Published: Apr 26, 2021
KRAKOW, Poland, April 26, 2021 /PRNewswire/ Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced the appointment of Vatnak Vat-Ho to the role of Chief Business Officer.
As Chief Business Officer, Mr. Vat-Ho will be responsible for a wide scope of corporate and business development activities at Ryvu including strategic positioning, partnering discussions, alliance management as well as investor interactions. I am truly honored to join the incredible team at Ryvu during such a high growth time it s an exciting opportunity to propel an already productive platform to bring important therapeutics to patients, commented Vatnak Vat-Ho, Chief Business Officer at Ryvu Therapeutics.